Surgical removal of breast tissue, used to treat or prevent breast cancer.
England has authorised Enhertu for routine NHS use for HER2‑low metastatic breast cancer, ensuring access for about 1,000 women annually. The decision follows a previous rejection over cost‑effectiveness and builds on a deal between NICE and drug makers AstraZeneca and Daiichi Sankyo. Scotland has already provided access since 2023.
A public look-back into CDDFT’s breast unit has harmed hundreds of patients, with 315 identified as harmed and 77 significantly harmed. The NHS and BBC reporting have prompted a potential extension to cases dating back to 2015. A board meeting today will decide the scope and timeframe as authorities consider further inquiries and safeguards.